KOBIO, the First Web-based Korean Biologics Registry Operated With a Unified Platform Among Distinct Disease Entities

Kim, Jinhyun; Koh, Jung Hee; Choi, Sung Jae; Jeon, Chan Hong; Kwok, Seung‐Ki; Kim, Seong-Kyu; Choi, Chan-Bum; Lee, Jaejoon; Lee, Chang‐Hoon; Nam, Eon Jeong; Park, Yong Bum; Lee, Shin-Seok; Kim, Tae‐Hwan; Park, Sung-Hwan; Koh, Eun‐Mi; Yoo, Dae-Hyun; Song, Yeong Wook; Kim, Hyoun‐Ah; Shin, Kichul; Choe, Jung‐Yoon

doi:10.4078/jrd.2021.28.4.176

Cited by 24 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The KOBIO registry is a nationwide web-based observational registry used to prospectively assess the clinical manifestations and outcomes of RA patients who initiate or switch to another b/tsDMARD. 16 All patients were adults (⩾18 years) and met the 2010 ACR/EULAR classification criteria for RA. 17 RA patients had follow-up assessments by individual investigators at 12-month intervals.…”

Section: Methodsmentioning

confidence: 99%

Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry

Koh

Lee²,

Kim

et al. 2022

Therapeutic Advances in Musculoskeletal

Self Cite

View full text Add to dashboard Cite

Background: Biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARD) are widely used for treatment of rheumatoid arthritis (RA), enabling patients to better achieve remission. Objective: The objective of the study was to investigate and compare remission rates in RA patients treated with different b/tsDMARDs during the period 2013–2019. Design: A longitudinal observational analysis was performed on data from a nationwide RA registry. Methods: Remission rates in the KOBIO-RA registry were defined by a disease activity score in 28 joints (DAS28), clinical disease activity index (CDAI), simplified disease activity index (SDAI), and Boolean-based assessment. After initiating treatment with b/tsDMARDs, yearly remission rates in response to b/tsDMARDs, either all or as subgroups (tumor necrosis factor-α inhibitors, tocilizumab, abatacept, and Janus kinase inhibitors), were investigated for 5 years. Sustained remission was defined as remission maintained for two consecutive years. Results: Patients ( N = 1805) who completed at least one follow-up visit were analyzed (mean age = 55 years; 83.2% female). At month 12, 56.0% of patients achieved remission based on DAS28-C-reactive protein (CRP), 36.2% on DAS28-erythrocyte sedimentation rate (ESR), 10.4% on CDAI, 12.7% on SDAI, and 12.9% on Boolean criteria. Sustained remission rates were 62%, 40%, 13%, 11%, and 8% for the DAS28-CRP, DAS28-ESR, Boolean, SDAI, and CDAI remission criteria, respectively. Remission rates using the DAS28 definition varied most among the b/tsDMARD subgroups. Conclusion: Assessment of sustained remission using the CDAI, SDAI, or Boolean criteria is more stringent, yet congruous with the DAS28-based criteria in RA patients treated with b/tsDMARDs.

show abstract

Section: Methodsmentioning

confidence: 99%

Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry

Koh

Lee²,

Kim

et al. 2022

Therapeutic Advances in Musculoskeletal

Self Cite

View full text Add to dashboard Cite

show abstract

“…The registry has enrolled new bDMARD users at initiation regardless of their previous exposure to bDMARD. Demographic, clinical, laboratory, and functional data of enrolled patients were prospectively recorded at baseline (at the time of new bDMARD initiation) and annual visits [ 22 ]. Besides, data were collected when the patients switched or discontinued bDMARD during the follow-up period.…”

Section: Methodsmentioning

confidence: 99%

Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry

Kim

Lee

et al. 2022

Rheumatol Ther

Self Cite

View full text Add to dashboard Cite

Introduction To compare the efficacy of abatacept and tumor necrosis factor inhibitor (TNFi) in patients with anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA) and identify those who benefit most from abatacept over TNFi. Methods This observational study identified RA patients who were ACPA-positive and initiated abatacept or TNFi from the Korean College of Rheumatology Biologics and Targeted therapy registry. Propensity score (PS) matching was performed to balance baseline confounding in abatacept- or TNFi-treated patients. The major endpoints were changes in Clinical Disease Activity Index (CDAI) and achievement of CDAI remission/low disease activity after 1 year of treatment. Subgroup analysis was mainly performed stratified by prior biologics use. Results A total of 291 PS-matched, ACPA-positive RA patients who initiated abatacept ( n = 97) and TNFi ( n = 194) were included. From baseline CDAI scores of 26.52 in the abatacept group and 26.38 in the TNFi group, the mean changes after 1 year were − 16.78 and − 13.61, respectively (difference − 3.17, p = 0.020). The proportion of patients achieving CDAI remission/low disease activity was 68.0% with abatacept and 52.6% with TNFi ( p = 0.013). In the subgroup analysis, patients that were biologics-naïve had better improvement in CDAI after treatment with abatacept than TNFi (difference − 3.35, p = 0.021). Conclusions This real-world study suggests that abatacept may have better clinical response compared to TNFi in patients with established ACPA-positive RA, especially in those that were biologics-naïve. Supplementary Information The online version contains supplementary material available at 10.1007/s40744-022-00467-4.

show abstract

“…This was an observational study using clinical data of patients with PsA registered in the KOBIO registry between December 2012 and March 2022 (Clinicaltrials.gov NCT01965132 ). 13 Patients were eligible for the study if they met the classification criteria for PsA (CASPAR). 14 Data of patients with AS were also obtained; patients fulfilled the 1984 modified New York criteria for the diagnosis of AS.…”

Section: Methodsmentioning

confidence: 99%

“… 10 11 12 The Korean College of Rheumatology Biologics and Targeted Therapy (KOBIO) registry is a large, prospective, observational, disease-based registry initiated in December 2012 that includes data on patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and PsA who were initiated on or switched to biologics or targeted synthetic disease-modifying antirheumatic drugs (DMARDs). 13 The registry data can provide information on the characteristics and comorbidities of patients in real-world clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Clinical Characteristics of Patients With Psoriatic Spondylitis Versus Those With Ankylosing Spondylitis: Features at Baseline Before Biologic Therapy

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Clinical characteristics and manifestations of psoriatic arthritis (PsA) have been extensively studied in western countries, yet data of Korean patients with PsA are very limited. We aimed to investigate the clinical traits of patients with PsA and dissect the characteristics of those with axial involvement. Methods In this observational study, we analyzed clinical data of 109 patients with PsA who were enrolled in the Korean College of Rheumatology Biologics and Targeted Therapy registry between December 2012 and March 2022 at the time point of initiating or switching to a biologic agent. Data from 2,221 patients with ankylosing spondylitis (AS) registered during the same period were also analyzed. We divided patients with PsA into patients with or without axial involvement and then added AS patients with psoriasis (total three subgroups) for comparative analyses. Results Asymmetric oligoarthritis was the most common clinical manifestation in patients with PsA, followed by symmetric polyarthritis and spondylitis. Our analysis indicated that methotrexate and sulfasalazine were the two most prescribed disease-modifying antirheumatic drugs for patients with PsA before starting biologic therapy. The patients with psoriatic spondylitis had more peripheral joint involvement ( P = 0.016), less prior uveitis ( P < 0.001), and lower human leukocyte antigen B27 (HLA-B27) positivity ( P < 0.001) than the AS patients with psoriasis. Furthermore, syndesmophytes and radiographic sacroiliitis were prevalent among patients with PsA and AS patients with psoriasis who had the HLA-B27 gene. Conclusion Our study shows that the degree of peripheral arthritis is less severe in Korean patients with PsA who require biologics and reestablishes that psoriatic spondylitis is a common and important clinical pattern in Korean patients with PsA. Trial Registration ClinicalTrials.gov Identifier: NCT01965132

show abstract

KOBIO, the First Web-based Korean Biologics Registry Operated With a Unified Platform Among Distinct Disease Entities

Cited by 24 publications

References 30 publications

Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry

Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry

Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry

Clinical Characteristics of Patients With Psoriatic Spondylitis Versus Those With Ankylosing Spondylitis: Features at Baseline Before Biologic Therapy

Contact Info

Product

Resources

About